PARIS–(BUSINESS WIRE)–Regulatory News: TP (Paris:TEP), a global leader in digital business services, today announced the appointment of Benoit Gabelle as Group Chief Financial Officer, effective immediately. Benoit Gabelle has served as Interim Group Chief Financial Officer since March 2026 when Jorge Amar was appointed Chief Executive Officer of TP. Benoit Gabelle joined TP as Group Deputy Chief Financial Officer in 2022, responsible for Financial Reporting & Consolidation, Corporate Acc
Month: September 2026
PARIS–(BUSINESS WIRE)–Regulatory News: TP (Paris:TEP), leader mondial des services aux entreprises en solutions digitales, annonce aujourd’hui la nomination de Benoit Gabelle au poste de Directeur Financier du groupe, avec effet immédiat. Benoit Gabelle occupait le poste de Directeur Financier du groupe par intérim depuis mars 2026, date à laquelle Jorge Amar a été nommé Directeur Général de TP. Benoît Gabelle a rejoint TP en 2022 en tant que Directeur Financier Adjoint du groupe, en charge d
HUNT VALLEY, Md.–(BUSINESS WIRE)–Teledyne Energy Systems, Inc., a subsidiary of Teledyne Technologies Incorporated (NYSE:TDY), has been selected to participate in NASA’s Announcement of Collaboration Opportunity, establishing a collaborative effort with NASA’s Glenn Research Center and Johnson Space Center to advance next-generation space power technology.Under the Space Act Agreement, Teledyne Energy Systems and NASA will work together to mature the company’s Hydrogen Electrical Power System
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF – February 23.09.2026 GFEB.LN IE000X8M8M80 700,002.00 USD 28,117,680.44 40.168
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest S&P 500 Dividend Aristocrats Target Income UCITS ETF 23.09.2026 KNG.LN IE000SNMGYT5 1,200,002.00 USD 24,337,926.34 20.282
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2026
- Revenue up 4.5% to 84.5 M€
- Proprietary products account for 37% of revenue
- 46% of revenue generated outside France
- Free cash flow of €4 million after investments
- Net debt of €147.4 million, including the EB Development shareholder loan
- Acquisition of CareDx’s Lab Solutions business finalized on June 30, 2026
Paris, September 24, 2026 – 17h40 – Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated results as of June 30, 2026, prepared in accordance with French standards and approved by the company’s Board of Directors at its meeting on September 24, 2026.
Eurobio Scientific’s results as of June 30, 2026 show growth in business activity. Revenue reached €84.5 million, up 4.5%, driven by recent acquisitions and growth in proprietary products. EBITDA stood at €15.8 million, and net income reached €4.7 million, compared to €2.4 million in the first half of 2025.
| In €m | June 30, 2026 | June 30, 2025 | Change | |
| Revenue | 84.5 | 80.8 | +5% | |
| Cost of goods sold | (44.4) | (42.9) | +3% | |
| Gross margin | 40.1 | 37.8 | +6% | |
| Gross margin rate | 47.5% | 47.3% | +0.2 pt | |
| Sales and Marketing expenses | (16.6) | (18.1) | -8% | |
| General and administrative expenses | (8.4) | (7.7) | +9% | |
| Other operating income and expenses | (4.8) | (4.3) | +12% | |
| Of which Research and Development expenses | (2.4) | (2.2) | +9% | |
| Amortization of goodwill | (1.9) | (1.9) | – | |
| Operating income | 8.5 | 5.8 | +45% | |
| Amortization of intangible assets arising from the PPA | (2.4) | (2.6) | – | |
| Amortization of other intangible assets | (3.2) | (2.9) | ||
| EBITDA | 15.8 | 13.2 | +20% | |
| Net financial income | (1.2) | (2.1) | -43% | |
| Net exceptional income | – | – | – | |
| Taxes | (2.5) | (1.4) | +76% | |
| Net income | 4.7 | 2.4 | +96% | |
| June 30, 2026 | Dec. 31, 2025 | |||
| Cash | 26.3 | 20.7 | ||
| Financial debt excluding finance leases | (9.0) | (10.1) | ||
| EB Development current account | (164.7) | (12.4) | ||
| Shareholders’ equity | 191.4 | 183.9 |
Business Performance
Eurobio Scientific reported revenue of €84.5 million for the first half of 2026, compared to €80.8 million in the first half of 2025, representing an increase of €3.6 million (+4.5%).
On a comparable pro forma basis—that is, excluding the impact of changes in scope resulting from acquisitions—revenue remained stable.
The impact of changes in scope primarily relates to the inclusion of the acquisition in Italy of the Life Sciences unit of Voden Medical Instruments Spa, which generated revenue of €3.8 million during the period.
Revenue from proprietary products totaled €31.3 million as of June 30, 2026, up 10% compared to the first half of 2025. Excluding the impact of changes in the scope of consolidation, growth stood at 7%. Proprietary products account for approximately 37% of the Group’s revenue, up one percentage point, thanks in particular to GenDx’s contribution in the field of transplantation and the product lines in infectious diseases and quality control. Revenue from distributed products reached €53.2 million, up 2%. Excluding changes in scope, it declined by 5%, primarily due to the end of tenders awarded to Eurobio Scientific for One Lambda products.
Internationally, revenue generated in Europe (excluding France), the United States, and Australia totaled €39.1 million, representing 46% of the Group’s revenue, compared to €32.8 million and 41% in the first half of 2025.
Information on Seegene
Eurobio Scientific reminds that it has been in partnership with the South Korean company Seegene since 2011 under a distribution agreement that generated approximately €48 million in revenue for fiscal year 2025 and €25.6 million as of June 30, 2026, representing a 12% increase compared to the first half of 2025.
As previously indicated, Seegene has expressed its desire to enter the French market directly effective January 1, 2027. The distribution agreement provides for Eurobio Scientific, with Seegene’s consent, to fulfill its private commercial contracts entered into prior to the distribution agreement’s expiration date for a maximum period of 3 years, as well as its public contracts for the duration of the awarded tenders.
The parties are continuing discussions to define the terms of this transition in accordance with the contractual provisions and applicable regulations. Eurobio Scientific reaffirms its strong commitment to continuing to serve its customers with high-quality products and services.
Changes in Operating Income and Net Income
The gross margin rate stood at 47.5%, up slightly from the first half of 2025 (47.3%), primarily due to the increase in the share of proprietary products in the revenue mix.
Operating expenses totaled €29.7 million, down €0.4 million compared to the first half of 2025 (-1.3%), and represented 35.1% of revenue, compared to 37.2% a year earlier.
Research and Development expenses totaled €2.4 million, compared to €2.2 million.
Marketing and sales expenses decreased by €1.6 million to €16.5 million, primarily due to the reorganization of the EndoPredict® and Prolaris® oncology sales activities that took place in the first half of 2025.
General and administrative expenses totaled €8.4 million, compared to €7.7 million.
Consequently, as of June 30, 2026, EBITDA reached €15.8 million, compared to €13.2 million as of June 30, 2025. Operating income after amortization and impairment of goodwill amounted to €8.5 million, compared to €5.8 million as of June 30, 2025.
Net financial income was negative at -€1.2 million, compared to -€2.1 million in the first half of 2025, primarily due to interest payments on the financial debt owed to EB Development. Extraordinary income was zero due to changes in accounting standards.
Net income thus totaled €4.7 million as of June 30, 2026, compared to €2.4 million as of June 30, 2025.
Free cash-flow of €4.0 million
The Group generated net operating cash flow of €7.5 million for the half-year, compared with €5.4 million in the first half of 2025. After €3.5 million in capital expenditures net of disposals, free cash flow before acquisitions amounted to approximately €4.0 million. The change in working capital had a negative impact of €5.0 million.
As of the end of June 2026, Eurobio Scientific had gross cash of €26.3 million. Loans and financial debt totaled €15.0 million, including approximately €4.8 million in finance leases, resulting in positive net cash of €17.3 million, excluding financing received from EB Development, which is classified as other liabilities.
The funding received from EB Development totaled €164.7 million, including €154.4 million received in June 2026 to finance the acquisition of CareDx’s Lab Solutions business.
Acquisition of CareDx’s Lab Solutions Business
On June 30, 2026, Eurobio Scientific completed the acquisition of CareDx’s Lab Solutions business, comprising the operations, products, technologies, and related assets primarily dedicated to transplant diagnostics. The transaction notably includes the AlloSeq® portfolio, designed specifically for HLA typing and chimerism monitoring, the associated software solutions, the QTYPE® product line, and other laboratory diagnostic assets transferred as part of the transaction. The corresponding assets and liabilities have been consolidated into the financial statements as of June 30, 2026; the acquisition therefore did not contribute to revenue or earnings for the first half of 2026.
Outlook and Proposed Public Tender Offer
Eurobio Scientific has a policy of not disclosing targets for the current fiscal year. In the medium term, the Group is pursuing its strategic priorities: developing proprietary products, expanding internationally, and entering new markets. In particular, the acquisition of Lab Solutions from CareDx strengthens its international position in transplant diagnostics.
On September 16, 2026, EB Development, the majority shareholder of Eurobio Scientific, announced its intention to file a voluntary tender offer followed by a mandatory tender offer for the Eurobio Scientific shares it does not yet hold, at a proposed price of €25.30 per share. On May 19, 20251, EB Development had declared it individually exceeded the thresholds of 90% of the Company’s share capital and voting rights and held, directly and by assimilation, 90.01% of Eurobio Scientific’s share capital and theoretical voting rights. Following the cancellation of 180,592 treasury shares decided on September 16, 2026, EB Development now directly holds 9,075,433 shares, representing 90.14% of the share capital and voting rights.
Upon the recommendation of the ad hoc committee established by the Company’s Board of Directors and composed of a majority of independent directors in accordance with the provisions of Article 261-1 of the General Regulations of the Autorité des Marchés Financiers (the “AMF”), the Board of Directors ofEurobio Scientific has appointed Ledouble, represented by Mr. Olivier Cretté and Mr. Jonathan Nilly (64, rue de la Boétie, 75008 Paris), as the independent appraiser responsible for drafting a report including a fairness opinion on the financial terms of the offer.
The documentation relating to the public buyout offer will be submitted to the AMF for review, and the completion of the offer remains subject to the AMF’s determination of compliance following its review.
Following the closing of the Offer, EB Development will initiate a mandatory buyout procedure, as minority shareholders hold less than 10% of Eurobio Scientific’s capital and voting rights. Minority shareholders will receive compensation equal to the price of the public buyout offer as part of the mandatory buyout procedure.
Availability of the 2026 half-yearly financial report
Eurobio Scientific made available to the public and filed with the French Financial Markets Authority (AMF) on 24 September 2026 its half-year financial report as at 30 June 2026.
The half-year financial report can be found on the company’s website at: www.eurobio-scientific.com under the heading “investors” / “regulated information” / “half-year financial reports”.
Disclaimer :
This press release has been prepared for information purposes only. It does not constitute an offer to purchase or exchange, or a solicitation of an offer to sell or exchange securities of Eurobio Scientific S.A.. The dissemination, publication or distribution of this press release may be restricted by law in certain jurisdictions and, consequently, any person in possession of this press release located in such jurisdictions must inform themselves about and comply with applicable legal restrictions. Neither Eurobio Scientific S.A., nor EB Development, nor its respective shareholders, advisors, or representatives accept any responsibility for the use by any person of this press release or its content, or more generally relating to this press release.
| About Eurobio Scientific Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, oncology, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Milan in Italy, Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, and Utrecht in The Netherlands. Eurobio Scientific’s controlling shareholder is the holding company EB Development, acting in concert with funds managed by NextStage AM and IK Partners, as well as members of the Company’s Board of Directors and senior management. For more information, please visit: www.eurobio-scientific.com The company is publicly listed on the Euronext Growth market in Paris |
| Contacts |
| Groupe Eurobio Scientific Denis Fortier, Chairman and CEO Olivier Bosc, Deputy CEO/ CFO Tel. +33(0) 1 69 79 64 80 |
Actus Mathieu Calleux Investors Relations Tel. +33(1) 53 65 68 68 – eurobio-scientific@actus.fr |
1 Threshold crossing declaration by the Offeror dated June 2, 2025 (D&I 225C0881).
Attachment
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF – November 23.09.2026 GNOV LN IE000OJ31JQ4 950,002.00 USD 35,916,617.44 37.807
DUBAI, United Arab Emirates–(BUSINESS WIRE)– #multibankgroup–MultiBank Group, has announced that its Founder and Chairman, Naser Taher, was named Financial Leader of the Year at the Gulf Business Awards 2026.
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF- August 23.09.2026 GAUG LN IE000TGSG3Y5 750,002.00 USD 28,347,406.81 37.796
Imagine learning that your home has been sold without your knowledge.
That is the potential consequence of home title theft, a form of fraud that can expose property owners to foreclosure, financial losses and legal disputes. KeyBank is providing tips to help you understand how the scheme works, recognize its warning signs and monitor property records so you can respond quickly to suspicious activity.
What is home title theft?
Home title theft, also called title fraud or deed fraud, occurs when a criminal uses forged documents to fraudulently transfer ownership of a property. Because property documents are filed in public records, the fraudulent transfer may go unnoticed until the legitimate owner receives an unexpected notice or discovers another problem.
After appearing as the owner on paper, a fraudster may attempt to:
- Sell the property to an unsuspecting buyer.
- Obtain a mortgage or home equity loan using the property.
- Rent the property and collect income.
- Take the proceeds and leave the legitimate owner to address the resulting financial and legal issues.
How does home title theft happen?
Home title theft commonly follows three stages:
1. A criminal obtains the homeowner’s personal information
Fraudsters may acquire personal information through data breaches, phishing emails, stolen mail, malware or purchases on the dark web.
2. The criminal creates forged property documents
Using the stolen information, the fraudster creates fraudulent property records, sometimes including a quitclaim deed, and forges the owner’s signature.
3. The documents are filed with a county office
The fraudulent documents are submitted to the county recorder’s office. Once recorded, public records may incorrectly show the fraudster as the property’s legal owner.
Who may face greater risk of title fraud?
Some properties and homeowners may warrant closer monitoring. These include:
- Seniors who may overlook early warning signs.
- Owners of vacation homes or rental properties.
- Estates belonging to recently deceased homeowners.
- Longtime homeowners with substantial equity and little or no remaining mortgage debt.
- People who have previously experienced identity theft or a data breach.
What are the warning signs of home title theft?
Homeowners should investigate unusual financial, legal or property-related activity. Potential warning signs include:
- Bills, loan statements or foreclosure notices that were not expected.
- Mail referencing a property sale or transfer the owner did not authorize.
- Property tax or utility bills issued in another person’s name.
- Unknown tenants or prospective buyers arriving at the property.
- Mortgages or credit inquiries the homeowner does not recognize.
- County notifications concerning documents the homeowner did not file.
No single sign necessarily establishes that title fraud has occurred, but unfamiliar activity should be verified promptly through the appropriate financial institution, credit bureau or county office.
How can homeowners help protect themselves?
Protect personal information and important documents
Homeowners can reduce exposure by shredding sensitive documents before disposal and storing original deeds in a fireproof safe. They should not provide one-time passcodes, PINs, passwords, Social Security numbers, birth dates, driver’s license numbers or other confidential information to unverified contacts.
Unexpected messages or requests should be verified by contacting the person or organization through a known phone number or trusted communication channel. KeyBank also recommends passwords containing at least 15 characters, with upper- and lowercase letters, numbers and symbols, as well as multifactor authentication whenever it is available.
Monitor credit reports and property records
Homeowners should review their credit reports for unfamiliar mortgages or home equity lines of credit. A credit-monitoring service can also provide alerts about changes to a credit report.
Some counties provide free property-fraud alerts. Homeowners can search for their county’s property fraud alert program and enroll if one is available. KeyBank also recommends checking the county recorder’s website for unauthorized filings and reviewing property records at least quarterly.
Review owner’s title insurance options
Owner’s title insurance is generally purchased once and is intended to protect the owner’s legal property rights. Depending on the terms and conditions of a specific policy, coverage may include legal expenses arising from a fraudulent ownership claim, financial losses connected to forgery or identity theft, and defense against invalid liens or claims.
Homeowners should consult their title insurance provider to understand the protections, exclusions and claim requirements in their own policy.
What should you do if you suspect home title theft?
A homeowner who discovers suspicious property activity should take the following steps:
- Contact the county recorder or registrar of deeds. Verify recent filings and request copies of documents that appear suspicious.
- Contact relevant banks or financial institutions. KeyBank clients can report suspected fraud through the online banking Security Center, call the Fraud Client Service Center at 1-800-433-0124, dial 711 for TTY/TRS, or visit a KeyBank branch.
- File a police report. A report establishes a legal record of the suspected fraud.
- Contact the three major credit bureaus. Obtain a credit report and consider placing fraud alerts and a credit freeze. The numbers listed by KeyBank are Equifax: 1-800-685-1111, Experian: 1-888-397-3742 and TransUnion: 1-800-909-9972.
- Report the identity theft to the Federal Trade Commission. Reports can be submitted at IdentityTheft.gov or by calling 1-877-438-4338.
- Contact a real estate attorney. Legal assistance may be needed to resolve a disputed property title.
- Notify the title insurance company. Homeowners with applicable coverage should contact the insurer about filing a claim.
Frequently asked questions about home title theft
Is home title theft the same as deed fraud?
Yes. The terms home title theft, title fraud and deed fraud are commonly used to describe schemes in which forged documents are used to fraudulently transfer property ownership.
Can someone take out a loan using a stolen property title?
A fraudster who appears as the owner in property records may attempt to obtain a mortgage or home equity loan against the property.
How can I check whether my property title has changed?
Review records through the county recorder’s website or office and request copies of any unfamiliar filings. If the county offers a property-fraud alert program, homeowners can enroll to receive notifications.
Does title insurance cover home title theft?
Coverage depends on the specific policy. Some owner’s title insurance policies may cover legal fees, losses related to forgery or identity theft, or defense against invalid claims and liens.
Where can KeyBank clients report suspected fraud?
KeyBank clients can use the online banking Security Center, call 1-800-433-0124, dial 711 for TTY/TRS, or visit a KeyBank branch.
Staying informed about fraud
KeyBank provides educational information about fraud, emerging scams and preventive strategies. Additional resources are available through KeyBank’s fraud information center at key.com/fraud.
This material is provided as general information only; the information contained herein may not apply to all situations. Nothing in this material shall be regarded as an offer or solicitation by KeyBank or its affiliates. This is not intended to be a recommendation or advice for your specific situation (including financial, accounting, legal, or tax advice). Consult appropriate professionals for your specific circumstances.
©2026 KeyCorp®. All rights reserved. KeyBank Member FDIC. CFMA 260921-5016128